Lumonus Revenue and Competitors
Employee Data
- Lumonus has 34 Employees.
Lumonus's People
Name | Title | Email/Phone |
---|
Lumonus Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | N/A | 2 | -50% | N/A | N/A |
#2 | N/A | 38 | 46% | N/A | N/A |
#3 | N/A | 65 | 20% | N/A | N/A |
#4 | N/A | 34 | N/A | N/A | N/A |
#5 | $7.5M | 148 | 10% | N/A | N/A |
#6 | $3.5M | 19 | -17% | N/A | N/A |
#7 | N/A | 12 | 0% | N/A | N/A |
#8 | N/A | 54 | 23% | N/A | N/A |
#9 | N/A | 20 | 5% | N/A | N/A |
#10 | $1.7M | 20 | -5% | N/A | N/A |
What Is Lumonus?
Hello. We’re Lumonus, a company focused on transforming cancer care. Our origin stems from experiencing first-hand the challenges that Providers face in delivering quality cancer care across global markets. We understand what it’s like to be a Provider, from managing clinical teams, understanding the needs of the patients and dealing with payors. It’s a hard job! At Lumonus we see the opportunity to transform how cancer care is delivered by empowering care teams through our twofold focus of user centric software products and also providing value-added services. We believe in the power of teams and how together they can achieve exceptional goals. Our team draws from years of provider experience and recognises the real-world problems and unmet needs that clinics of all sizes encounter. We embrace innovative thinking and constantly search for new possibilities. Our Products and Services: Oncology Software, Remote Dosimetry, Physics Commissioning, Comprehensive Physics, Clinical and Operations strategy consulting Servicing regions: USA, Australia and UK
keywords:N/AN/A
Total Funding
34
Number of Employees
N/A
Revenue (est)
N/A
Employee Growth %
N/A
Valuation
N/A
Accelerator
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $8.5M | 34 | 6% | N/A |
#2 | $6M | 34 | -11% | N/A |
#3 | $5.7M | 34 | -6% | N/A |
#4 | $4.1M | 34 | 3% | N/A |
#5 | $35M | 34 | -6% | N/A |